Vera Kiyasova, Director of Clinical Development at NMD Pharma, is heading to Cambridge, USA to present at the
@CMTRF’s 2025 Global CMT Research Convention. Taking place from 25-27 September, this event is focused on connecting individuals living with Charcot-Marie-Tooth disease (
#CMT) with researchers, industry partners, investors, and regulatory agencies looking to develop new therapeutic approaches and, ultimately, a cure for this rare hereditary neuropathy.
Vera’s presentations will take place on 27 September during the ‘Patient Experience’ Day, which NMD Pharma is also sponsoring. The first, ‘From Discovery to Delivery – the Life Cycle of Drug Development,’ is being held from 9:30-10:00EDT and will provide key insights into the
#DrugDiscovery and development processes, as well as necessary regulatory procedures that must be undertaken to bring a treatment to patients. In addition, from 13:00-13:15EDT, she will also provide key information on NMD Pharma’s ongoing Phase 2
#ClinicalTrial in patients living with CMT Type 1 and Type 2 during the ‘Current and Emerging Clinical Trials for CMT’ session.
We’re looking forward to connecting with the global CMT community at this event – join us to learn more about working to enhance muscle function and endurance in individuals living with neuromuscular diseases.
For the full event agenda visit:
cmtconvention.cmtrf.org/
#CMTRF #Conference #NMDPharma #Biotech #Innovation #CharcotMarieTooth #NeuromuscularDisease #RareDisease